Yıl: 2014 Cilt: 40 Sayı: 3 Sayfa Aralığı: 170 - 179 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

The treatment of late-onset hypogonadism

Öz:
Late-onset hypogonadism (LOH) in aging men is a clinical and biochemical syndrome caused by an age-re -lated decline in testosterone. Despite published in guidelines and recommendations, uncertainty surroundsthe profle of clinical symptoms as well as the biochemical threshold of diagnosis. The only evidence-basedtreatment of late-onset hypogonadism is testosterone replacement therapy. The actual available evidenceof the long-term risks and outcomes of testosterone-replacement therapy remains very limited, and care -fully designed placebo-controlled trials of testosterone administration to assess the risks and benefts ofsuch a therapy are required. Until such evidence is available, testosterone treatment should be restricted toelderly men with very low testosterone levels in the presence of clinical symptoms, and the advantages anddisadvantages need to be accurately assessed. Careful monitoring of potential side effects is necessary. Thepurpose of this review is to discuss what is known and what remains unclear with respect to the benefts andrisks of testosterone replacement treatment.
Anahtar Kelime:

Konular: Üroloji ve Nefroloji
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment, and monitoring of lateonset hypogonadism in males: ISA, ISSAM, and EAU recommen- dations. J Androl 2006;27:135-7. [CrossRef]
  • 2. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJi et al. International Society of Andrology (ISA); International Society for the Study of the Aging Male (ISSAM); European Association of Urology (EAU): Investigation, treatment, and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005;48:1-4. [CrossRef]
  • 3. Ucer O, Gumus B, Okur M, Karatas TC, Buyuksu C. Does Late- Onset Hypogonadism Occur by Aging? The Evaluation of IIEF, Ams-Q and Biochemical Parameters. Turkiye Klinikleri J Med Sci 2010;30:73-8. [CrossRef]
  • 4. Mäkinen JI, Huhtaniemi I. Androgen replacement therapy in late- onset hypogonadism: current concepts and controversies - a mini- review. Gerontology 2011;57:193-202. [CrossRef]
  • 5. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011;52:657-63. [CrossRef]
  • 6. Feldman HA, Longcope C, Derby C, Johannes C, Araujo AB, Coviello A, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98. [CrossRef]
  • 7. Morley JE, Perry HM. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Biol 2003;85:367-73. [CrossRef]
  • 8. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinol- ogy of aging. Science 1997;278:419-24. [CrossRef]
  • 9. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late- onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASArecommendations. Eur Urol 2009;55:121-30. [CrossRef]
  • 10. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005;8:56-8. [CrossRef]
  • 11. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: a User’s Manual, Revised 2nd Printing Boston MA (USA): The Health Institute, New England Medical Center, 1994.
  • 12. Lee DM, O’Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, et al. The European Male Aging Study (EMAS): design, methods and recruitment. Int J Androl 2009;32:11-24. [CrossRef]
  • 13. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-42. [CrossRef]
  • 14. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26. [CrossRef]
  • 15. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new aging males symptoms’rating scale. Aging Male 1999;2:105-14. [CrossRef]
  • 16. Cangüven Ö, Gürkan L, Horuz R, Albayrak S, Kadıoğlu A. Symptom questionnaire form in the aging male Turkish validation study. Androloji Bulletin 2005;21:93-6.
  • 17. Heinemann LA, Moore C, Dinger JC, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS scale. Health Qual Life Outcomes 2006;4:23. [CrossRef]
  • 18. Kim JW, Moon DG. Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism. Korean J Urol 2011;52:725-35. [CrossRef]
  • 19. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late- onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recom mendations. J Androl 2009;30:1-9. [CrossRef]
  • 20. Iwamoto T, Yanase T, Horie H, Namiki M, Okuyama A. Late-onset hypogonadism (LOH) and androgens: validity of the measurement of free testosterone levels in the diagnostic criteria in Japan. I nt J Urol 2009;16:168-74. [CrossRef]
  • 21. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59. [CrossRef]
  • 22. Da Ros CT, Averbeck MA. Twenty-five milligrams of clomiphene citrate presents positive effect on treatment of male testosterone deficiency - a prospective study. Int Braz J Urol 2012;38:512-8. [CrossRef]
  • 23. Bassil N, Alkaade S, Morley JE. The benefits and risks of tes - tosterone replacement therapy: a review. Ther Clin Risk Manag 2009;5:427-48.
  • 24. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
  • 25. Marberger M, Wilson TH, Rittmaster RS. Low serum testoster- one levels are poor predictors of sexual dysfunction. BJU Int 2011;108:256-62. [CrossRef]
  • 26. Travison TG, Araujo AB, Kupelian V, O’Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007;92:549-55. [CrossRef]
  • 27. Rhoden EL, Teloken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002;167:1745-8. [CrossRef]
  • 28. Nigro N, Christ-Crain M. Testosterone treatment in the aging male: myth or reality? Swiss Med Wkly 2012;19:142.
  • 29. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35. [CrossRef]
  • 30. Bolo-a ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized place- bo- controlled trials. Mayo Clinic Proc 2007;82:20-8. [CrossRef]
  • 31. Reyes Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med 2007;4:1757-62. [CrossRef]
  • 32. Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007;30:880-8. [CrossRef]
  • 33. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8. [CrossRef]
  • 34. Lugg JA, Rajfer J, González-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-501. [CrossRef]
  • 35. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-16. [CrossRef]
  • 36. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8. [CrossRef]
  • 37. Corona G, Maggi M. The role of testosterone in erectile dysfunc - tion. Nat Rev Urol 2010;7:46-56. [CrossRef]
  • 38. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003;67:1521-6.
  • 39. Tuck SP, Francis RM. Testosterone, bone and osteoporosis. Front Horm Res 2009;37:123-32. [CrossRef]
  • 40. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523-7. [CrossRef]
  • 41. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72. [CrossRef]
  • 42. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008;299:39-52. [CrossRef]
  • 43. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta- analysis. Clin Endocrinol (Oxf) 2005;63:280-93. [CrossRef]
  • 44. Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, et al. Testosterone use inmen and its effects on bone health. A systematic review and meta-analysis of randomized placebo-con - trolled trials. J Clin Endocrinol Metab 2006;91:2011-6. [CrossRef]
  • 45. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22. [CrossRef]
  • 46. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physicalfunction, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639-50. [CrossRef]
  • 47. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002;5:98-102. [CrossRef]
  • 48. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-7. [CrossRef]
  • 49. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-37. [CrossRef]
  • 50. Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 2010;16:570-6. [CrossRef]
  • 51. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906. [CrossRef]
  • 52. Bosland MC. The role of steroid hormones in prostate carcinogen- esis. J Natl Cancer Inst Monogr 2000;27:39-66. [CrossRef]
  • 53. Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011;59:244-9. [CrossRef]
  • 54. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-5.
  • 55. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Alen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83. [CrossRef]
  • 56. Goldenberg SL, Koupparis A, Robinson ME. Differing levels of testosterone and the prostate: a physiological interplay. Nat Rev 2011;8:365-77.
  • 57. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized con - trolled trial. JAMA 2006;296:2351-61. [CrossRef]
  • 58. Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010;105:1397-401. [CrossRef]
  • 59. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011;14:53-8. [CrossRef]
  • 60. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middleaged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol 2005;60:1451-7. [CrossRef]
  • 61. Cui Y, Zong H, Yang C, Yan H, Zhang Y. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta- analysis. Int Urol Nephrol 2013;45:979-87. [CrossRef]
  • 62. Spivak JL. The blood in systemic disorders. Lancet 2000;355:1707- 12. [CrossRef]
  • 63. Zitzmann M, Nieschlag E. Androgens and erythropoiesis. In: Nieschlag E, Behre HM, editors. Testosterone: action, defi- ciency, substitution. Cambridge: Cambridge University Press; 2004.p.283-96.
  • 64. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75. [CrossRef]
  • 65. Bremner WJ. Testosterone deficiency and replacement in older men. N Engl J Med 2010;363:189-91. [CrossRef]
  • 66. Brunton SA, Sadovsky R. Late-onset male hypogonadism and testosterone replacement therapy in primary care. J Fam Pract 2010;59:1-8.
APA Üçer O, GÜMÜŞ B (2014). The treatment of late-onset hypogonadism. , 170 - 179.
Chicago Üçer Oktay,GÜMÜŞ BİLAL-İ HABEŞ The treatment of late-onset hypogonadism. (2014): 170 - 179.
MLA Üçer Oktay,GÜMÜŞ BİLAL-İ HABEŞ The treatment of late-onset hypogonadism. , 2014, ss.170 - 179.
AMA Üçer O,GÜMÜŞ B The treatment of late-onset hypogonadism. . 2014; 170 - 179.
Vancouver Üçer O,GÜMÜŞ B The treatment of late-onset hypogonadism. . 2014; 170 - 179.
IEEE Üçer O,GÜMÜŞ B "The treatment of late-onset hypogonadism." , ss.170 - 179, 2014.
ISNAD Üçer, Oktay - GÜMÜŞ, BİLAL-İ HABEŞ. "The treatment of late-onset hypogonadism". (2014), 170-179.
APA Üçer O, GÜMÜŞ B (2014). The treatment of late-onset hypogonadism. Türk Üroloji Dergisi/Turkish Journal of Urology, 40(3), 170 - 179.
Chicago Üçer Oktay,GÜMÜŞ BİLAL-İ HABEŞ The treatment of late-onset hypogonadism. Türk Üroloji Dergisi/Turkish Journal of Urology 40, no.3 (2014): 170 - 179.
MLA Üçer Oktay,GÜMÜŞ BİLAL-İ HABEŞ The treatment of late-onset hypogonadism. Türk Üroloji Dergisi/Turkish Journal of Urology, vol.40, no.3, 2014, ss.170 - 179.
AMA Üçer O,GÜMÜŞ B The treatment of late-onset hypogonadism. Türk Üroloji Dergisi/Turkish Journal of Urology. 2014; 40(3): 170 - 179.
Vancouver Üçer O,GÜMÜŞ B The treatment of late-onset hypogonadism. Türk Üroloji Dergisi/Turkish Journal of Urology. 2014; 40(3): 170 - 179.
IEEE Üçer O,GÜMÜŞ B "The treatment of late-onset hypogonadism." Türk Üroloji Dergisi/Turkish Journal of Urology, 40, ss.170 - 179, 2014.
ISNAD Üçer, Oktay - GÜMÜŞ, BİLAL-İ HABEŞ. "The treatment of late-onset hypogonadism". Türk Üroloji Dergisi/Turkish Journal of Urology 40/3 (2014), 170-179.